Bragar Eagel & Squire, P.C. is investigating potential claims against Unicycive Therapeutics, Inc. on behalf of Unicycive stockholders. The investigation concerns whether Unicycive violated federal securities laws or engaged in other unlawful business practices. The inquiry follows Unicycive's June 30, 2026 announcement that the FDA issued a second Complete Response Letter for its kidney disease therapy application, citing the same third-party manufacturing deficiencies as a prior letter. On that news, Unicycive shares fell $3.01, or approximately 39%, from $7.70 on June 29 to close at $4.69 on June 30, 2026. Investors who purchased or acquired Unicycive stock and suffered losses are encouraged to contact the firm.
Unicycive Therapeutics IncFDA issued second Complete Response Letter for kidney disease therapy due to manufacturing deficiencies, causing 39% stock drop.